DexCom, Inc. (NASDAQ:DXCM) Stake Boosted by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. grew its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 124.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,872 shares of the medical device company's stock after buying an additional 31,525 shares during the quarter. DexCom accounts for approximately 0.9% of Lecap Asset Management Ltd.'s investment portfolio, making the stock its 8th biggest holding. Lecap Asset Management Ltd.'s holdings in DexCom were worth $3,884,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Bank Pictet & Cie Europe AG raised its holdings in shares of DexCom by 1.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock worth $8,637,000 after purchasing an additional 2,010 shares during the period. Allworth Financial LP raised its holdings in shares of DexCom by 60.9% in the 4th quarter. Allworth Financial LP now owns 1,081 shares of the medical device company's stock worth $84,000 after purchasing an additional 409 shares during the period. Sanctuary Advisors LLC raised its holdings in shares of DexCom by 21.7% in the 4th quarter. Sanctuary Advisors LLC now owns 18,061 shares of the medical device company's stock worth $1,405,000 after purchasing an additional 3,226 shares during the period. Finally, Private Advisor Group LLC raised its holdings in shares of DexCom by 33.8% in the 4th quarter. Private Advisor Group LLC now owns 15,149 shares of the medical device company's stock worth $1,178,000 after purchasing an additional 3,831 shares during the period. Institutional investors own 97.75% of the company's stock.

Insider Activity

In other news, Director Nicholas Augustinos sold 2,618 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $81.69, for a total transaction of $213,864.42. Following the completion of the transaction, the director now directly owns 37,083 shares of the company's stock, valued at approximately $3,029,310.27. This represents a 6.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the transaction, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,724 shares of company stock valued at $2,157,034. Insiders own 0.32% of the company's stock.

DexCom Trading Up 1.5%

DexCom stock traded up $1.29 during mid-day trading on Friday, hitting $86.33. The company's stock had a trading volume of 4,632,374 shares, compared to its average volume of 4,393,451. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The stock has a market cap of $33.85 billion, a price-to-earnings ratio of 64.43, a price-to-earnings-growth ratio of 1.81 and a beta of 1.46. The business has a 50 day moving average price of $81.70 and a 200-day moving average price of $79.59. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business's revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 earnings per share. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research reports. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Piper Sandler lowered their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Mizuho assumed coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Cfra Research upgraded shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Finally, Canaccord Genuity Group lifted their price objective on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, DexCom has an average rating of "Moderate Buy" and an average price target of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.